£6.0M
The funding will support Phase I clinical trials for the company lead antimicrobial candidate.
CT
Centauri Therapeutics
Centauri Therapeutics develops novel immunotherapies to target multidrug-resistant Gram-negative bacteria.
United Kingdom—Founded 2019
£7.0MTotal raised
A British biotechnology firm developing immunotherapies to combat drug-resistant bacterial infections using its proprietary Alphamer platform.
Categories
Team
SL
Stuart Lawson
Founder
JS
Jennifer Schneider
Chief Executive Officer
Investors
- £6.0M
- £1.0MPPACELead
Funding history
£1.0M
Centauri Therapeutics has secured £1m from PACE to develop its Alphamer technology targeting drug-resistant bacterial strains.